lucky 777 download

The thrilling competitions of the 52nd four-day National Athletics Championship 2024 continued for the second day in Multan, showcasing the exceptional talents of athletes representing various institutions from across the country. In the women’s 10,000-meter race, WAPDA’s Maria Bibi secured first place, while HEC’s Natasha Hussain claimed the second position. The women’s 400-meter hurdles title was clinched by WAPDA’s Musarrat Shaheen, followed by teammate Noreen Jabar in second place. Meanwhile, Ghazala Ramzan, also from WAPDA, emerged victorious in the 100-meter hurdles. In the women’s 800-meter race, Army’s Rabeela Farooq finished first with WAPDA’s Iram Shehzadi taking second place. In the men’s 10,000-meter race, WAPDA’s Sohail Amir grabbed the top spot, while Pakistan Army’s Muhammad Riaz secured second place. The women’s long jump event saw HEC’s Amtal Rehman clinching the first position, while the men’s pole vault was won by Army’s Jafar Ashraf. In the men’s 400-meter race, WAPDA’s Shajar Abbas emerged victorious. Meanwhile, the women’s 200-meter race title went to Army’s Tameem Khan. In the women’s high jump event, WAPDA’s Rabab took first place, followed by HEC’s Amtal Rehman in second. In the men’s shot put, Army’s Jamshed Ali claimed the top spot, with WAPDA’s Shafqat Ali finishing second. The championship drew a diverse audience, including people from various walks of life, local residents, and students, who enthusiastically cheered for the athletes and appreciated their remarkable performances. The 52nd National Athletics Championship continues to be a testament to Pakistan’s rising talent in the field of athletics.

Kamala’s coda: What’s next for defeated US VP Harris?Oliver Glasner: Crystal Palace are heading in right direction after Ipswich win

Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

Jean-Philippe Mateta struck in the second half with the only real piece of quality in a nervy encounter between two struggling teams. It is now two wins and three draws from the last six matches for Glasner’s side, whose winter revival is gathering pace nicely following a sticky start to the campaign. “I feel very happy, we’re all very pleased with the result, it was not the best performance but the result was more important,” said the Eagles boss. “Most of the time we controlled the game and we scored an amazing goal, a fantastic finish from JP. “We had more chances to decide the game but we couldn’t, but I think the win was well deserved. “We didn’t give them any chances from open play and with a clean sheet you can always take the win. “It’s a big win. Now it’s not time to sit back and relax but to keep going. In four days we face Manchester City. We stay humble. There are still many things to improve but we are on the right path.” Ipswich looked the likelier to score as a low-key first half drew to a close and were denied by a point-blank save by Dean Henderson from Harry Clarke’s near-post header. Shortly after the interval Wes Burns got clear down the right and lifted an inviting cross towards Liam Delap, whose header was straight at Henderson. However, from out of nowhere Palace conjured up a lightning counter-attack to go ahead on the hour. Eberechi Eze led the charge before feeding Mateta, who surged forward with a couple of stepovers before brushing off the attention of Jacob Greaves and finishing superbly past Arijanet Muric. It was the French forward’s sixth goal of the season, and his first away from Selhurst Park. Back came Ipswich with Leif Davis fizzing in another cross for Delap, who somehow mistimed his jump and completely missed the ball from six yards. As time ticked down Greaves looped a header against the far post, with the rebound just eluding substitute Ali-Al Hamadi. “Frustrating night,” said Town boss Kieran McKenna. “It was a tight first half, we weren’t fantastic in terms of the flow of the game and didn’t create as many opportunities as we wanted. But having said that neither did our opponents. “In the second half we conceded a really poor goal and that proved decisive. We can do better than we did tonight.”

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on December 2, 2024, the Compensation Committee of Zentalis’ Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 3,028,800 shares of the Company’s common stock to Julie Eastland, who joined the Company as Chief Executive Officer and President, non-qualified stock options to purchase an aggregate of 712,650 shares of the Company’s common stock to Dr. Ingmar Bruns, who joined the Company as Chief Medical Officer, and non-qualified stock options to purchase an aggregate of 753,660 shares of the Company’s common stock to five newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.66 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options granted to Ms. Eastland have a 10-year term and will vest over four years in equal monthly installments until the stock options are fully vested. The stock options granted to the other newly hired employees have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego. For more information, please visit www.zentalis.com . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals . ZENTALIS ® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. Contacts: Elizabeth Hickin Vice President, Investor Relations ehickin@zentalis.com

Toll Brothers Announces New Community, Enchanted Bluff, is Now Open Near San Antonio, TexasPanic among spectators at soccer game kills at least 56 in the West African nation of Guinea